Immunophotonics raises $10 million, names new CEO

Immunophotonics closed an initial $10 million Series C financing and promoted President Robert H. Arch, Ph.D., to chief executive officer effective Sept. 1, 2026. The money is slated to support development of IP-001 and the company’s Phase 2 programs as the biotech advances toward clinical and regulatory milestones.

Why it matters: - The new financing gives Immunophotonics added runway to push IP-001 through ongoing non-clinical and clinical work. - The capital is expected to support Phase 2 programs, planned operations, and key clinical and regulatory milestones across the portfolio. - IP-001 is being tested in multiple solid tumor indications, making continued funding central to the company’s near-term development path.

What happened: - Immunophotonics said it closed an initial $10 million Series C financing on Sept. 1, 2026. - The company also made a leadership change effective the same day. - Miguel Zubizarreta stepped down as interim CEO and remained on the Board of Directors. - Robert H. Arch, Ph.D., was promoted from president to president and CEO.

The details: - The financing is expected to fund planned operations through several anticipated clinical milestones and data readouts. - IP-001 is the company’s lead investigational drug candidate. - The drug is a proprietary glycan polymer designed to generate tumor antigen depots and act as a multimodal immune stimulant. - IP-001 is intended to prolong tumor antigens released by ablation, recruit and activate antigen-presenting cells, increase antigen uptake, and promote an adaptive immune response. - Immunophotonics said Arch brings more than two decades of experience advancing immunotherapy programs from idea to clinical trials. - His background spans scientific research, business development, corporate strategy, and clinical development at biotechnology and multinational pharma companies. - Chairman Jonathan Knowles said the board was grateful for Zubizarreta’s leadership during an important fundraising period. - Zubizarreta said he has confidence in Arch’s ability to lead the company and will continue supporting Immunophotonics as a board member. - Immunophotonics is a privately owned clinical-stage biotech focused on interventional immuno-oncology. - The company’s headquarters are in St. Louis, Missouri, and Bern, Switzerland. - More information is available in the company’s announcement.

Between the lines: - The financing and CEO transition together signal a shift from fundraising mode to execution mode. - Retaining Zubizarreta on the board suggests the company wants continuity as it pursues clinical readouts and broader strategic opportunities. - Arch’s mix of scientific and commercial experience points to a leadership focus on advancing both development and corporate strategy.

What's next: - Immunophotonics plans to use the new capital to continue IP-001 development and advance its clinical Phase 2 programs. - The company is working toward additional clinical and regulatory milestones. - Future data readouts from its development programs will help determine the next stage for IP-001 and the broader platform.

The bottom line: - Immunophotonics now has fresh funding and a new chief executive as it tries to turn IP-001’s early clinical momentum into later-stage progress.